While reporting financial results for the first quarter on Wednesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, trimmed its adjusted earnings guidance for the full-year 2025, while maintaining annual sales outlook.
The company said the outlook is revised to reflect the negative impact from anticipated one-time charge of approximately $0.06 per share related to license agreement with Hengrui Pharma.
The outlook also absorbs an estimated $200 million of additional costs for tariffs implemented to date.
For fiscal 2025, Merck now projects adjusted earnings in a range of $8.82 to $8.97 per share, lower than the prior guidance range of $8.88 to $9.03 per share. Sales are still expected between $64.1 billion and $65.6 billion.
On average, 23 analysts polled expect the company to report earnings of $8.94 per share on sales of $65.01 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.